PD-L1抑制剂诱导的甲状腺炎与癌症患者更好的总生存期相关
该回顾性队列研究纳入2016年6月1日至2018年1月30日在Mayo Clinic Rochester接受阿替利珠单抗和阿维鲁单抗治疗的91例癌症患者,中位随访10.1个月,发现21%发生新发甲状腺功能障碍,4%原有甲减加重;甲状腺IRAE与更长总生存期相关,校正混杂因素后死亡风险比为0.49(95%CI 0.25-0.99,p=0.034)。
要点
- PD-L1抑制剂治疗患者中21%发生新发甲状腺功能障碍,4%原有甲减加重。
- 甲状腺IRAE中位发生于2剂(6周)后,48%需甲状腺激素替代,无需激素或停药。
- 发生甲状腺IRAE者总生存期更长,校正后HR 0.49(95%CI 0.25-0.99,p=0.034)。
核心结论
- PD-L1抑制剂导致免疫介导的甲状腺炎,是最常见的内分泌IRAE;多数病例支持治疗即可,无需激素或停用免疫治疗。
- PET扫描甲状腺弥漫性18FDG摄取增高可能预测甲状腺炎发生,TPO抗体可能有助于识别其严重程度。
- 甲状腺炎可能是抗肿瘤免疫反应的生物标志物,强调需进一步明确其潜在机制。
研究设计与样本
- 回顾性队列研究,纳入2016年6月1日至2018年1月30日在Mayo Clinic Rochester接受阿替利珠单抗和阿维鲁单抗治疗的癌症患者,中位随访10.1个月。
主要发现
- 91例接受PD-L1抑制剂治疗的患者中,19例(21%)发生新发甲状腺功能障碍,其中14例表现为甲减、5例表现为甲状腺毒症(3例进展为甲减、2例恢复至甲状腺功能正常),4例(4%)原有甲减加重。
- 甲状腺IRAE中位发生于2剂(6周)后,48%需要甲状腺激素替代,无一例需要激素或停用免疫治疗。
- 基线TPO抗体>9 IU/mL的4例患者中2例发生甲状腺IRAE;有无甲状腺IRAE者中位TPO抗体滴度无差异,但显性甲减者高于亚临床甲减者(5 vs. 0.3 IU/mL,p=0.003),接受甲状腺激素替代者高于观察者(5.5 vs. 0.3,p=0.008)。
- PET扫描甲状腺弥漫性18FDG摄取增高在甲状腺IRAE者中发生率为71%,无甲状腺IRAE者为6%(p=0.001)。
- 发生甲状腺IRAE者总生存期更长(p=0.027),校正潜在混杂因素后死亡率更低(HR 0.49 [95%CI 0.25-0.99],p=0.034)。
临床怎么用
- 作者指出多数PD-L1抑制剂相关甲状腺炎支持治疗即可,无需激素或停用免疫治疗。
- 作者指出PET扫描甲状腺弥漫性18FDG摄取增高可能预测甲状腺炎发生,TPO抗体可能有助于识别其严重程度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid immune-related adverse events (IRAEs) have been reported more frequently with programmed cell death protein-1 (PD-1) inhibitors than cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, but there is limited data describing endocrinopathies from programmed cell death protein-ligand 1 (PD-L1) inhibitors. This study characterizes thyroid IRAEs in cancer patients treated with PD-L1 inhibitors and examines the impact on overall survival. Methods: This is a retrospective cohort study of cancer patients treated with atezolizumab and avelumab at the Mayo Clinic, Rochester, Minnesota, from June 1, 2016 to January 30, 2018, and followed for a median of 10.1 months. Thyroid IRAEs were characterized as new onset hypothyroidism, thyrotoxicosis, and worsening of pre-existing hypothyroidism. Results: Of 91 patients treated with a PD-L1 inhibitor, 19 (21%) developed new onset thyroid dysfunction, of whom 14 presented with hypothyroidism and 5 with thyrotoxicosis (3 progressed to hypothyroidism and 2 returned to euthyroidism), and 4 (4%) had worsening of pre-existing hypothyroidism. Thyroid IRAEs occurred after a median of two doses (6 weeks), 48% required thyroid hormone replacement, and none required steroids or discontinuation of immunotherapy. Two out of four patients with thyroid peroxidase (TPO) antibody >9 IU/mL at baseline developed thyroid IRAEs. Median TPO antibody titer was not different between those with and without thyroid IRAEs but was higher in those with overt than those with subclinical hypothyroidism (5 vs. 0.3 IU/mL, p = 0.003) and those prescribed thyroid hormone replacement as compared with observation (5.5 vs. 0.3, p = 0.008). Diffusely increased thyroid 18-fluorodeoxyglucose (18FDG) uptake on positron emission tomography (PET) scan occurred in 71% with thyroid IRAE as compared with 6% without thyroid IRAEs (p = 0.001). Patients who developed thyroid IRAEs had longer overall survival (p = 0.027) and lower mortality (hazard ratio 0.49 [95% CI 0.25-0.99], p = 0.034) after adjusting for potential confounders. Conclusions: PD-L1 inhibitors lead to immune-mediated thyroiditis, the most frequent endocrine IRAE. In most cases, management is supportive without requiring steroids or discontinuation of immunotherapy. Diffusely increased thyroid 18FDG uptake on PET scan may predict the occurrence of thyroiditis, whereas TPO antibodies may help identify its severity. Thyroiditis may be a biomarker for antitumor immune response, highlighting the need to further characterize its underlying mechanism.
引用
- Kotwal A, Kottschade L, Ryder M, et al. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid. 2020. PMID: 31813343. doi:10.1089/thy.2019.0250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。